Breaking News Instant updates and real-time market news.

RDFN

Redfin

$27.56

0.86 (3.22%)

, EGN

Energen

$50.21

0.65 (1.31%)

10:29
08/22/17
08/22
10:29
08/22/17
10:29

On The Fly: Top five analyst initiations

Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Redfin (RDFN) initiated with a Sector Perform at RBC Capital, Hold rating at Stifel, an Outperform at Oppenheimer and Neutral at Goldman Sachs. 2. Energen (EGN) initiated with an Outperform at Imperial Capital. 3. Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital. 4. Revance (RVNC) initiated with an Outperform at JMP Securities. 5. Pacira (PCRX) initiated with a Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RDFN

Redfin

$27.56

0.86 (3.22%)

EGN

Energen

$50.21

0.65 (1.31%)

PXD

Pioneer Natural

$128.63

0.69 (0.54%)

RVNC

Revance

$22.70

-0.45 (-1.94%)

PCRX

Pacira

$35.75

-0.05 (-0.14%)

  • 29

    Aug

  • 06

    Sep

  • 25

    Sep

  • 02

    Nov

RDFN Redfin
$27.56

0.86 (3.22%)

08/22/17
BOFA
08/22/17
INITIATION
Target $28
BOFA
Neutral
Redfin initiated with a Neutral at BofA/Merrill
BofA/Merrill initiated Redfin with a Neutral and a $28 price target.
08/22/17
OPCO
08/22/17
INITIATION
Target $31
OPCO
Outperform
Redfin initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jason Helfstein started Redfin with an Outperform rating and $31 price target.
08/22/17
STFL
08/22/17
INITIATION
STFL
Hold
Redfin initiated with a Hold at Stifel
Stifel analyst John Egbert started coverage of Redfin with a $24 price target and a Hold rating. The analyst says that the company's model of paying its agents a salary and charging "below-market commissions" is "disruptive," but he thinks that the stock is currently fairly valued. However, he is upbeat on the company's longer term outlook.
08/22/17
RBCM
08/22/17
INITIATION
RBCM
Sector Perform
Redfin initiated with a Sector Perform at RBC Capital
RBC Capital analyst Mark Mahaney started coverage of Redfin with a $28 price target and a Sector Perform rating. He says that the company has strong fundamentals and "should...create shareholder value" over the "long-term." However, he says the stock is currently "reasonably valued." Target $28. .
EGN Energen
$50.21

0.65 (1.31%)

08/11/17
GHSC
08/11/17
UPGRADE
Target $46
GHSC
Neutral
Energen Energen upgraded to Neutral from Sell at Seaport Global
Seaport Global analyst Mike Kelly upgraded Energen to Neutral and increased its price target to $46 from $38 citing inreased confidence in execution and asset quality. The analyst said Energen had impressive results from both its Gen 3 completions and from its pattern/batch completions in the Midland and Delaware basins.
07/20/17
JPMS
07/20/17
DOWNGRADE
Target $53
JPMS
Neutral
Energen downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Michael Glick downgraded Energen (EGN) to Neutral saying he's repositioning his ratings ahead of the Q2 reporting season toward names that can perform well in a lower commodity price environment. The analyst calls Parsley Energy (PE) and Diamondback Energy (FANG) his top picks in the small-to-mid cap Exploration & Production space. He lowered his price target for Energen shares to $53 from $60.
06/21/17
GHSC
06/21/17
DOWNGRADE
Target $38
GHSC
Sell
Energen downgraded to Sell from Neutral at Seaport Global
Seaport Global analyst Mike Kelly downgraded Energen to Sell and slashed its price target to $38 from $61 to reflect a new commodity price deck. Seaport Global's Energy team reduced its long-term oil forecast to $40/bbl from $50/bbl to reflect "relentless" US production growth. The firm sees the potential for the oil market to be "significantly over supplied in 2018 and cut its oil price forecast for first half 2017 to $45/bbl from $55/bbl and first half 2018 to $35/bbl from $55/bbl.
08/22/17
IMPC
08/22/17
INITIATION
Target $61
IMPC
Outperform
Energen initiated with an Outperform at Imperial Capital
Imperial Capital analyst Irene Haas initiated Energen with an Outperform and a $61 price target. Energen has divested its non-Permian and non E&P assets during the downturn and has built up a sizeable inventory in the Delaware Basin and Midland, the analyst wrote in a report. Haas said Energen now has a robust growth profile, and has demonstrated it is a good operator.
PXD Pioneer Natural
$128.63

0.69 (0.54%)

08/08/17
DBAB
08/08/17
NO CHANGE
DBAB
Deutsche views Pioneer Natural, peers as 'significantly oversold'
Deutsche Bank analyst Ryan Todd believes Pioneer Natural Resources (PXD) as well as the Permian Exploration & Production space are "significantly oversold" following Pioneer's Q2 results last week. The higher gas content of the production stream started an investor debate around the long-term risks to Permian production and resource value, Todd tells investors in a research note. He calls investor fears "wildly overblown" and is a buyer of the group, especially Pioneer Natural. The analyst has Buy ratings on the shares as well as Anadarko Petroleum (APC), ConocoPhillips (COP), Chevron (CVX) and Devon Energy (DVN).
08/08/17
STFL
08/08/17
NO CHANGE
STFL
Pioneer Natural shares oversold, says Stifel
Stifel analyst Derrick Whitfield says that Pioneer is "oversold" on both fundamentals and technicals. He says the company has "a modest execution overhang" following its Q2 results, but he thinks the stock has priced in the worst case scenario for dealing with salt water disposal over the long-term. The analyst believes that the company has addressed its execution issues while the stock is 20% undervalued. He keeps a $236 price target and a Buy rating on the shares.
08/09/17
GSCO
08/09/17
NO CHANGE
GSCO
Buy
Pioneer Natural share pullback overdone, says Goldman Sachs
Goldman analyst Brian Singer said the recent sharp pullback in Pioneer Natural shares is overdone. The analyst said lowered 2017 oil mix guidance is being incorrectly interpreted by the Street as a negative for Permian economics. Singer does not believe there has been any underperformance of oil production to more gas and the same oil and reiterates his Buy rating.
08/22/17
IMPC
08/22/17
INITIATION
Target $160
IMPC
Outperform
Pioneer Natural initiated with an Outperform at Imperial Capital
Imperial Capital analyst Irene Haas initiated Pioneer Natural with an Outperform and a $160 price target saying it is a first mover and leader in the Midland Basin. Recent drilling issues are being remediated and concerns of much gassier Midland Basin are overdone, the analyst wrote. Haas views Pioneer as a high growth, low net debt opportunity.
RVNC Revance
$22.70

-0.45 (-1.94%)

05/19/17
RHCO
05/19/17
NO CHANGE
RHCO
Revance data positive, says SunTrust
After Revance reported data on its RT002 for Cervical Dystonia, SunTrust analyst John Boris says that the greater than 24 week duration for the drug versus 8-12 week for competing drugs is "impressive." The analyst recommends buying the stock ahead of upcoming data.
08/22/17
JMPS
08/22/17
INITIATION
JMPS
Outperform
Revance initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started coverage of Revance with a $34 price target and an Outperform rating. He says that the efficacy of the company's RT002 injectable botulinum toxin appears to last six months, versus three months for competing treatments. The analyst thinks that Revance's treatment "will have cost and quality-of-life benefits for patients," and he expects the stock to rise going forward.
07/21/17
CANT
07/21/17
INITIATION
Target $50
CANT
Overweight
Revance initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Revance Therapeutics with an Overweight rating and $50 price target. The analyst sees positive news flow for the company's key programs in development driving both estimates and the shares higher. Chen expect Revance to report positive results before the end of the year for its Phase 3 pivotal trials for glabellar lines and Phase 2 results for its new indication, plantar fasciitis.
11/29/16
AGIS
11/29/16
INITIATION
Target $28
AGIS
Buy
Revance initiated with a Buy at Aegis
Aegis analyst Difei Yang initiated Revance with a Buy and a $28 price target.
PCRX Pacira
$35.75

-0.05 (-0.14%)

08/21/17
JANY
08/21/17
UPGRADE
JANY
Neutral
Pacira upgraded to Neutral from Sell at Janney Capital
08/21/17
08/21/17
UPGRADE
Target $36

Neutral
Pacira upgraded to Neutral after pullback at Janney Capital
As previously reported, Janney Capital analyst Ken Trbovich upgraded Pacira to Neutral from Sell, saying he no longer sees significant downside after the stock's nearly 30% decline over the past month. However, he believes upside is dependent on growth for Exparel accelerating to at least the upper-end of the company's guidance of 12%-27% in the second half. He keeps a $36 fair value estimate on Pacira shares.
08/22/17
NEED
08/22/17
INITIATION
NEED
Buy
Pacira initiated with a Buy at Needham
Needham analyst Serge Belanger started coverage of Pacira with a $55 price target and a Buy rating. He says that data indicate that the company's non-opioid pain treatment has a :"compelling" growth outlook. The analyst thinks that the company's sales will rise as soon as 2H17, and he believes that the decline in the stock has created an attractive entry point.
07/27/17
JANY
07/27/17
NO CHANGE
Target $36
JANY
Sell
Pacira overvalued even after mixed nerve block data selloff, says Janney Capital
Janney Capital analyst Ken Trbovich noted that Pacira shares sold off 15% after the company reported mixed Phase 3 data from its nerve block studies, but he believes the stock is still overvalued. While he still believes the label expanding sNDA will be approved 6 months after the sNDA is filed, he does not believe the filing can happen until Q4 of this year, leading him to push back his projections of Exparel Rx growth until Q2 of 2018. Trbovich maintains a Sell rating and $36 fair value estimate on Pacira shares.

TODAY'S FREE FLY STORIES

GM

General Motors

$39.42

0.32 (0.82%)

11:43
09/23/17
09/23
11:43
09/23/17
11:43
Periodicals
GM to eliminate shift at Tennessee SUV plant on 'moderating' sales, WSJ says »

General Motors has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.25

0.19 (0.35%)

11:34
09/23/17
09/23
11:34
09/23/17
11:34
Periodicals
Wells Fargo hires law firm to prepare CEO for Senate appearance, Reuters says »

Wells Fargo has hired law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 03

    Oct

  • 13

    Oct

  • 22

    Oct

  • 29

    Nov

  • 15

    Jan

EADSY

Airbus

$23.06

-0.01 (-0.04%)

11:27
09/23/17
09/23
11:27
09/23/17
11:27
Periodicals
Airbus in talks to sell all or part of Premium Aerotec, Reuters says »

Airbus is said to be in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$102.11

0.56 (0.55%)

11:06
09/23/17
09/23
11:06
09/23/17
11:06
Hot Stocks
Quest Diagnostics 'disappointed' with proposed PAMA 2018 Medicare payment rates »

Quest Diagnostics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

IRBT

iRobot

$76.14

-3.8 (-4.75%)

10:58
09/23/17
09/23
10:58
09/23/17
10:58
Periodicals
iRobot suffering after onslaught of SharkNinja cheaper models, Barron's says »

In a follow up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$69.33

0.42 (0.61%)

, SNPS

Synopsys

$80.36

0.3 (0.37%)

10:47
09/23/17
09/23
10:47
09/23/17
10:47
Periodicals
Xilinx, Synopsys are 'rising stars' amid natural evolution of AI, Barron's says »

As everyday items get…

XLNX

Xilinx

$69.33

0.42 (0.61%)

SNPS

Synopsys

$80.36

0.3 (0.37%)

CDNS

Cadence Design

$38.88

0.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

UTX

United Technologies

$115.01

0.51 (0.45%)

, COL

Rockwell Collins

$130.48

0.09 (0.07%)

10:42
09/23/17
09/23
10:42
09/23/17
10:42
Periodicals
Major aircraft makers, suppliers face off, Barron's says »

While United Technologies…

UTX

United Technologies

$115.01

0.51 (0.45%)

COL

Rockwell Collins

$130.48

0.09 (0.07%)

BA

Boeing

$256.45

0.41 (0.16%)

EADSY

Airbus

$23.06

-0.01 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

GPRO

GoPro

$10.75

-0.19 (-1.74%)

10:33
09/23/17
09/23
10:33
09/23/17
10:33
Periodicals
Key events may create 'short squeeze' in GoPro stock, Barron's says »

GoPro, a heavily shorted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.91

0.18 (0.61%)

, RACE

Ferrari

$113.47

-0.1 (-0.09%)

10:17
09/23/17
09/23
10:17
09/23/17
10:17
Periodicals
Honda $200,000 Acura NSX lacks Ferrari 'raw appeal,' Barron's says »

Acura, Honda's (HMC)…

HMC

Honda

$29.91

0.18 (0.61%)

RACE

Ferrari

$113.47

-0.1 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$48.16

0.19 (0.40%)

10:07
09/23/17
09/23
10:07
09/23/17
10:07
Periodicals
Oracle shares could return 20% in a year, Barron's says »

Oracle is a latecomer to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SIX

Six Flags

$58.96

1.14 (1.97%)

09:59
09/23/17
09/23
09:59
09/23/17
09:59
Periodicals
Six Flags may have peaked, Barron's says »

Investors have had an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

, AVXS

AveXis

$92.11

-4.03 (-4.19%)

09:51
09/23/17
09/23
09:51
09/23/17
09:51
Periodicals
Gene therapy may be nearing 'major breakthrough,' Baron's says »

Gene therapy is rapidly…

ONCE

Spark Therapeutics

$85.15

-1.95 (-2.24%)

AVXS

AveXis

$92.11

-4.03 (-4.19%)

RGNX

Regenxbio

$28.25

-1.15 (-3.91%)

BOLD

Audentes Therapeutics

$27.31

-0.1 (-0.36%)

VYGR

Voyager Therapeutics

$17.50

-0.22 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 12

    Oct

  • 12

    Jan

  • 22

    Sep

AET

Aetna

$153.57

0.18 (0.12%)

, ANTM

Anthem

$182.86

-0.64 (-0.35%)

09:25
09/23/17
09/23
09:25
09/23/17
09:25
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CNC

Centene

$92.22

1.48 (1.63%)

CI

Cigna

$182.74

0.61 (0.33%)

HNT

Health Net

HUM

Humana

$239.09

0.45 (0.19%)

MOH

Molina Healthcare

$65.32

2.81 (4.50%)

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

WCG

WellCare

$167.16

1.1 (0.66%)

AOBC

American Outdoor Brands

$15.01

-0.15 (-0.99%)

RGR

Sturm, Ruger

$51.00

-1.85 (-3.50%)

WMT

Wal-Mart

$79.53

-0.48 (-0.60%)

PEP

PepsiCo

$111.85

-0.95 (-0.84%)

TGT

Target

$58.99

0.66 (1.13%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

MSFT

Microsoft

$74.41

0.2 (0.27%)

AMZN

Amazon.com

$955.10

-9.55 (-0.99%)

TWTR

Twitter

$17.61

0.03 (0.17%)

GOOGL

Alphabet Class A

$943.26

-4.29 (-0.45%)

GOOG

Alphabet

$928.53

-3.92 (-0.42%)

FB

Facebook

$170.54

-0.57 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

  • 22

    Oct

  • 24

    Oct

  • 08

    Nov

  • 16

    Nov

  • 21

    Nov

  • 29

    Nov

  • 20

    Feb

AVA

Avista

$51.40

0.1 (0.19%)

18:47
09/22/17
09/22
18:47
09/22/17
18:47
Hot Stocks
Avista receives commission decision in Oregon natural gas rate case »

Avista's natural gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

BMWYY

BMW

$34.00

0.083 (0.24%)

18:40
09/22/17
09/22
18:40
09/22/17
18:40
Periodicals
BMW to build new 8 series in Dingolfing from 2018, Reuters reports »

BMW intends to build its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$33.37

0.67 (2.05%)

18:20
09/22/17
09/22
18:20
09/22/17
18:20
Hot Stocks
Cisco completes acquisition of Springpath »

Cisco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

BMY

Bristol-Myers

$63.36

0.03 (0.05%)

18:12
09/22/17
09/22
18:12
09/22/17
18:12
Hot Stocks
Bristol-Myers announces FDA approval of Opdivo »

Bristol-Myers announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 18

    Oct

  • 26

    Oct

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

INSE

Inspired Entertainment

$13.60

0.3 (2.26%)

17:38
09/22/17
09/22
17:38
09/22/17
17:38
Hot Stocks
Inspired Entertainment COO Wilson leaving by reason of redundancy »

On September 21, Inspired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MNOV

MediciNova

$6.18

0.3 (5.10%)

17:30
09/22/17
09/22
17:30
09/22/17
17:30
Syndicate
Breaking Syndicate news story on MediciNova »

MediciNova files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

ISRG

Intuitive Surgical

$1,031.52

1.31 (0.13%)

17:25
09/22/17
09/22
17:25
09/22/17
17:25
Conference/Events
Intuitive Surgical to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

GD

General Dynamics

$205.41

-0.31 (-0.15%)

17:21
09/22/17
09/22
17:21
09/22/17
17:21
Hot Stocks
General Dynamics Electric Boat awarded $341.2M government contract modification »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRS

Coherus Biosciences

$12.85

0.3 (2.39%)

17:19
09/22/17
09/22
17:19
09/22/17
17:19
Syndicate
Breaking Syndicate news story on Coherus Biosciences »

Coherus Biosciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FIBK

First Interstate

$36.90

0.3 (0.82%)

17:18
09/22/17
09/22
17:18
09/22/17
17:18
Syndicate
First Interstate files to sell $250M of Class A common stock »

The shelf registration…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

, NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

17:08
09/22/17
09/22
17:08
09/22/17
17:08
Hot Stocks
National Research launches metric to measure healthcare consumer loyalty »

NRC Health launched the…

NRCIA

National Research, also tag NRCIB

$37.45

0.55 (1.49%)

NRCIB

National Research, also tag NRCIA

$54.30

0.31 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CC

Chemours

$51.79

-0.16 (-0.31%)

, HON

Honeywell

$141.75

0.89 (0.63%)

16:58
09/22/17
09/22
16:58
09/22/17
16:58
Hot Stocks
Chemours files appeal concerning SNAP 20 rule to regulate HFCs »

The Chemours Company (CC)…

CC

Chemours

$51.79

-0.16 (-0.31%)

HON

Honeywell

$141.75

0.89 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.